Oncolytics Biotech (ONCY) Operating Leases (2018 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Operating Leases of $563000.0 for Q4 2025, little changed year-over-year from $563373.3 in Q4 2024, and up 39.1% quarter-over-quarter from $404735.7 in Q3 2025.
Oncolytics Biotech (ONCY) Operating Leases (2018 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Operating Leases for 8 consecutive years, with $563000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Leases changed 0.07% year-over-year to $563000.0; the TTM figure through Dec 2025 stood at $563000.0 (changed 0.07% YoY), while the FY2025 annual figure was $563000.0, changed 0.36% from the prior year.
- Operating Leases climbed to $563000.0 in Q4 2025 per ONCY's latest filing, from $404735.7 in the prior quarter.
- Across five years, Operating Leases topped out at $703523.3 in Q1 2024 and bottomed at $213015.3 in Q4 2023.
- Historically, Operating Leases has averaged $399071.8 across 5 years, with a median of $377924.8 in 2021.
- Annual changes were most pronounced in 2022 — Operating Leases tumbled 47.12% — and 2024, when it surged 164.48%.
- Oncolytics Biotech's Operating Leases stood at $519635.1 in 2021, then sank by 47.12% to $274790.2 in 2022, then decreased by 22.48% to $213015.3 in 2023, then soared by 164.48% to $563373.3 in 2024, then slipped by 0.07% to $563000.0 in 2025.
- Business Quant data shows ONCY's Operating Leases at $563000.0 in Q4 2025, $404735.7 in Q3 2025, and $430862.4 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - |
| 10 | Oncolytics Biotech | 98.29 Mn | 98.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 448,000.00 |
| Dec 31, 2025 | 563,000.00 |
| Sep 30, 2025 | 404,735.70 |
| Jun 30, 2025 | 430,862.36 |
| Mar 31, 2025 | 494,810.70 |
| Dec 31, 2024 | 563,373.27 |
| Sep 30, 2024 | 595,972.42 |
| Jun 30, 2024 | 651,446.23 |
| Mar 31, 2024 | 703,523.32 |
| Dec 31, 2023 | 213,015.30 |
| Sep 30, 2023 | 240,935.54 |
| Jun 30, 2023 | 257,580.55 |
| Mar 31, 2023 | 279,605.23 |
| Dec 31, 2022 | 274,790.20 |
| Sep 30, 2022 | 226,085.86 |
| Jun 30, 2022 | 259,107.72 |
| Mar 31, 2022 | 242,747.90 |
| Dec 31, 2021 | 519,635.13 |
| Sep 30, 2021 | 351,113.82 |
| Jun 30, 2021 | 415,199.04 |